10x GenomicsTXG +2.85%62 Altman Z-Score is 13.00 as of Jun. 27, 2026, which is 20% below its 10-year median of 16.35. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $19.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 662 Healthcare Providers & Services companies, 10x Genomics ranks better than 93.2% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 13 is strong.
10x Genomics has a Altman Z-Score of 13.00, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for 10x Genomics's Altman Z-Score or its related term are showing as below:
TXG'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.71 Med: 16.35 Max: 65.77
Current: 13
During the past 9 years, 10x Genomics's highest Altman Z-Score was 65.77. The lowest was 1.71. And the median was 16.35.
10x Genomics (NAS:TXG) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
10x Genomics Altman Z-Score Related Terms
10x Genomics Altman Z-Score Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
10x Genomics's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.5475
+
1.4
*
-1.5004
+
3.3
*
-0.0189
+
0.6
*
23.1305
+
1.0
*
0.6289
=
13.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
10x Genomics (TXG) has a Altman Z-Score of 13.00 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on 10x Genomics and its competitors. This is 20% below median its historical median of 16.35. Over the past decade, 10x Genomics' Altman Z-Score has ranged from 1.71 to 65.77. According to the industry distribution chart, 10x Genomics ranks #45 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 6.8%.
Is 10x Genomics' Altman Z-Score too high?
10x Genomics' current Altman Z-Score of 13.00 is 20% below median its 10-year median of 16.35. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 65.77. The Healthcare Providers & Services industry median Altman Z-Score is 2.36. 10x Genomics' value of 13.00 is 450.8% above this industry median. Based on the distribution chart, 10x Genomics ranks #45 out of 662 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Altman Z-Score compare to WAY and DOCS?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #45 out of 662 companies for Altman Z-Score. This places 10x Genomics in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.36. 10x Genomics' value of 13.00 is 450.8% above this benchmark. Historically, 10x Genomics' own Altman Z-Score has ranged from 1.71 to 65.77 over the past decade. While the company's 10-year median is 16.35 vs. the industry median of 2.36, 10x Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.36, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Altman Z-Score of 13.00 is 450.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Altman Z-Score is 13.00, which is 20% below median its own 10-year median of 16.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.00, compared to a current price of $36.70 — trading 93.2% above its estimated fair value. The current Altman Z-Score is 13.00, which is 20% below median its 10-year median of 16.35 and 450.8% above the Healthcare Providers & Services industry median of 2.36. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For 10x Genomics (TXG), the current Altman Z-Score is 13.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $36.70 is trading 93.2% above its estimated GF Value™ of $19.00.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Altman Z-Score: 13.00 (20% below median its 10-year median of 16.35)
GF Value™: $19.00 vs. price of $36.70 (93.2% above fair value)
Industry Position: 450.8% above the Healthcare Providers & Services median (#45 of 662)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score
Get the complete analysis for TXG
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
